Leerink Partners Maintains Outperform on Kardigan, Lowers Price Target to $36
Kardigan: Q3 Earnings Snapshot
Kardigan Reports Third Quarter 2026 Financial Results and Recent Business Updates
Kardigan Q3 EPS $(0.64) Beats $(0.77) Estimate
Kardigan to Participate in the Jefferies Global Healthcare Conference
Kardigan Extends Phase 2 Ataciguat Trial Assessment, Targets 2027 Results
Kardigan, Inc. (KARD) Discusses Aortic Stenosis Progression Data and KATALYST-AV Baseline Findings Transcript
Kardigan, Inc. (KARD) Discusses Aortic Stenosis Progression Data and KATALYST-AV Baseline Findings - Slideshow
Kardigan Completes Enrollment in Phase 2b KATALYST-AV Trial and Announces New Evidence Supporting Patient Selection and Endpoints for the Evaluation of Ataciguat in Aortic Stenosis
Kardigan Completes Enrollment In Phase 2b KATALYST-AV Trial Of Ataciguat In People With Aortic Stenosis
HC Wainwright & Co. Initiates Coverage On Kardigan with Buy Rating, Announces Price Target of $42
Cantor Fitzgerald Initiates Coverage On Kardigan with Overweight Rating, Announces Price Target of $50
Baird Initiates Coverage On Kardigan with Outperform Rating, Announces Price Target of $43
William Blair Initiates Coverage On Kardigan with Outperform Rating
UBS Initiates Coverage On Kardigan with Buy Rating, Announces Price Target of $25
Kardigan Announces Appointment of Kristin Reinke to its Board of Directors
Kardigan: Funded Precision Cardiology Offers More Than Pipeline Diversification
Kardigan to Present at Two September Investor Conferences
JP Morgan Maintains Overweight on Kardigan, Lowers Price Target to $46
Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.